+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Sale

Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968783
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Sclerosis Market is projected to reach USD 36.11 Billion in 2026. It is expected to continue growing at a CAGR of 8.29%, reaching USD 58.34 Billion by 2032.

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system that affects the brain, spinal cord, and optic nerves. According to the Atlas of MS, approximately 2.8 million people live with MS worldwide, with diagnosis most often occurring in early adulthood and women affected about twice as often as men. These epidemiological realities make MS a high-priority therapeutic area for disease-modifying therapies, relapse management, neuroprotection research, rehabilitation, and long-term care coordination.

For pharmaceutical and biotechnology leaders, the multiple sclerosis market is shaped by the continued expansion of high-efficacy therapies, growing use of biomarkers and MRI monitoring, and increasing pressure to demonstrate durable outcomes in real-world populations. Executive decision-making now depends on integrating clinical efficacy, safety, adherence, patient access, and payer evidence into a unified MS commercialization strategy.

Transformative Shifts in the MS Landscape

The MS treatment landscape has shifted from delayed escalation toward earlier use of higher-efficacy disease-modifying therapies in appropriate patients, supported by evidence that early inflammatory control can reduce relapse activity and MRI lesion accumulation. Monoclonal antibodies, S1P receptor modulators, fumarates, anti-CD20 therapies, and immune reconstitution approaches have expanded treatment choice while increasing the need for individualized risk-benefit assessment.

Another major shift is the growing emphasis on progressive MS, disability accumulation independent of relapse activity, and patient-reported outcomes. Stakeholders are moving beyond annualized relapse rate alone and focusing on confirmed disability progression, cognition, fatigue, mobility, treatment persistence, and quality of life. This transformation is intensifying investment in biomarkers, longitudinal registries, and therapies that address neurodegeneration as well as inflammation.

Cumulative Impact of Artificial Intelligence in MS

Artificial intelligence is increasingly influencing MS research, diagnosis, clinical trial design, and post-market evidence generation. AI-assisted MRI analysis can support lesion detection, lesion volume measurement, brain atrophy assessment, and longitudinal comparison, helping clinicians and researchers manage the high imaging burden associated with MS monitoring. These tools are most valuable when validated against expert neuroradiology workflows and integrated with clinical context.

In drug development, machine learning is being applied to patient stratification, endpoint enrichment, digital biomarkers, and real-world evidence analytics. AI can help identify progression patterns, predict relapse risk, and improve trial efficiency, but its cumulative impact depends on transparent algorithms, diverse datasets, regulatory-grade validation, privacy safeguards, and avoidance of bias across sex, ethnicity, geography, and disability status.

Key Regional Insights Across the MS Market

North America remains a leading MS market due to high diagnosis rates, advanced neurology infrastructure, strong reimbursement pathways, and rapid adoption of specialty therapies, particularly in the United States and Canada. Europe also represents a mature MS environment, supported by national health systems, MS registries, academic neurology networks, health technology assessment processes, and established use of disease-modifying therapies across major economies.

Asia-Pacific is expanding as awareness, MRI availability, specialty neurology access, and healthcare spending rise, although prevalence and diagnosis patterns vary substantially across China, Japan, South Korea, India, Australia, and ASEAN markets. Latin America shows improving access in Brazil, Mexico, and other larger systems, but affordability and uneven specialist coverage remain constraints. The Middle East is strengthening tertiary care and specialty pharmacy channels, particularly in GCC countries, while Africa faces underdiagnosis, limited MRI access, and significant treatment access gaps despite rising recognition of MS across urban centers.

Key Group Insights for MS Stakeholders

Within ASEAN, MS remains comparatively underdiagnosed, but the market is developing as tertiary hospitals, MRI capacity, and neurologist training improve in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries benefit from high healthcare investment and expanding specialty medicine access, creating opportunities for MS centers of excellence, infusion services, and structured patient support programs.

The European Union is central to MS evidence generation, regulatory harmonization, pharmacovigilance, and long-term registry-based research, while BRICS economies combine large patient populations with uneven reimbursement and access maturity across Brazil, Russia, India, China, and South Africa. G7 countries continue to influence global MS treatment standards through clinical trial leadership, payer scrutiny, and adoption of high-efficacy therapies. NATO members overlap significantly with high-income MS markets, where security of pharmaceutical supply chains, data governance, and health system resilience are increasingly relevant to sustained access.

Key Country Insights in Multiple Sclerosis

The United States is the largest commercial opportunity for MS therapies, driven by specialty drug adoption, active clinical trial participation, and broad availability of neurologic subspecialty care, although affordability and payer management remain major market-shaping factors. Canada has among the world’s highest reported MS prevalence and strong registry infrastructure, while Mexico and Brazil are expanding access through public and private channels but face budget and regional access disparities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature MS treatment pathways, with Germany often serving as an early-adoption market and the UK emphasizing health technology assessment and evidence-based access. Russia has a sizable MS population but faces procurement and access variability. In Asia-Pacific, China and India offer long-term development potential as diagnosis improves, Japan and South Korea provide advanced specialty care and established neurology networks, and Australia has high MS awareness, strong clinical networks, and structured reimbursement for approved therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence strategies that show durable clinical value beyond relapse reduction, including disability progression, cognition, fatigue, MRI activity, brain volume loss, adherence, and patient-reported outcomes. Market access teams should align early with payers on comparative effectiveness, budget impact, and real-world persistence, particularly as biosimilars and generics intensify pricing pressure in established therapy classes.

Organizations should also strengthen patient support, safety monitoring, and treatment navigation to improve adherence and continuity of care. High-priority opportunities include progressive MS, remyelination, neuroprotection, digital monitoring, biomarker-guided therapy selection, and AI-enabled trial optimization. Partnerships with MS registries, academic centers, imaging networks, and advocacy organizations can improve data quality, support equitable access, and accelerate patient-centered innovation.

Research Methodology

This executive summary is built from a structured review of verified secondary sources, including global MS epidemiology references, regulatory agency communications, peer-reviewed clinical literature, health technology assessment trends, clinical guideline updates, and publicly available information from recognized neurology and MS organizations. The analysis emphasizes data consistency, clinical relevance, and market applicability across therapeutic, diagnostic, regional, and access dimensions.

The methodology combines epidemiological assessment, treatment landscape mapping, regional access evaluation, competitive trend interpretation, and technology impact analysis. Insights were synthesized to support executive decision-making while avoiding unsupported claims, speculative forecasts, market sizing, market share estimates, or unverified market assumptions.

Conclusion

The multiple sclerosis market is moving toward earlier intervention, higher-efficacy treatment, precision monitoring, and broader evidence requirements. While disease-modifying therapies have changed the outlook for many patients, major unmet needs remain in progressive disease, disability prevention, cognitive impairment, fatigue, equitable access, and long-term safety optimization.

For pharmaceutical and biotechnology executives, success will depend on delivering differentiated clinical value, validating outcomes in real-world populations, and building integrated access strategies across mature and emerging MS markets. Organizations that combine scientific innovation with patient-centered evidence and responsible AI adoption will be best positioned to support the next phase of MS care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Multiple Sclerosis Market, by Multiple Sclerosis Type
7.1. Introduction
7.2. Primary
7.3. Secondary
7.4. Relapsing
7.5. Progressive-Relapsing
8. Multiple Sclerosis Market, by Treatment Type
8.1. Introduction
8.2. Disease-Modifying Therapies
8.2.1. Injectable Therapies
8.2.2. Oral Therapies
8.2.3. Monoclonal Antibodies
8.3. Symptomatic Treatments
8.4. Acute Relapse Management
9. Multiple Sclerosis Market, by Mechanism of Action
9.1. Introduction
9.2. Immunomodulators
9.3. Immunosuppressants
9.4. Cell Depletion Therapies
9.5. S1P Receptor Modulators
9.6. Anti-adhesion Molecules
10. Multiple Sclerosis Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Intravenous
11. Multiple Sclerosis Market, by Drug Type
11.1. Introduction
11.2. Biologics
11.3. Small Molecules
12. Multiple Sclerosis Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Homecare Settings
13. Multiple Sclerosis Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Multiple Sclerosis Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Multiple Sclerosis Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. AstraZeneca PLC
17.3. Bayer AG
17.4. Biogen Inc.
17.5. Bristol-Myers Squibb Company
17.6. Celgene Corporation
17.7. F. Hoffmann-La Roche Ltd.
17.8. Genentech, Inc.
17.9. GlaxoSmithKline plc
17.10. Horizon Therapeutics plc
17.11. Johnson & Johnson
17.12. Merck KGaA
17.13. Mitsubishi Tanabe Pharma Corporation
17.14. Novartis AG
17.15. Otsuka Holdings Co., Ltd.
17.16. Pfizer Inc.
17.17. Sanofi S.A.
17.18. Takeda Pharmaceutical Company Limited
17.19. Teva Pharmaceutical Industries Ltd.
17.20. TG Therapeutics, Inc.
17.21. UCB S.A.
17.22. Viela Bio, Inc.
List of Figures
FIGURE 1. GLOBAL MULTIPLE SCLEROSIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MULTIPLE SCLEROSIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PRIMARY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PRIMARY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PRIMARY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL SECONDARY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL SECONDARY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL SECONDARY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RELAPSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RELAPSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RELAPSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 89. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 90. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 91. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 92. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 113. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 114. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 115. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 118. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 130. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 132. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 133. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 134. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 135. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 138. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 139. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 140. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 141. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 143. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 146. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 147. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 148. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 149. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 151. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 163. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 164. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 165. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 170. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 171. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 172. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 173. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 175. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 178. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 179. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 180. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 181. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 182. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 183. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 184. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 186. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 187. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 189. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 190. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 195. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 197. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 198. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 200. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 203. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 205. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 206. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 208. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 211. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 212. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 213. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 214. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 216. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 227. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 228. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 229. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 230. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 232. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 235. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 236. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 237. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 238. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 240. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 243. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 244. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 245. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 246. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 248. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 251. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 252. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 253. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 254. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 256. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 259. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 260. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 261. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 262. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 264. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 268. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 269. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 283. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 284. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 285. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 286. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 288. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2017-2032 (USD MILLION)
TABLE 291. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 292. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2017-2032 (USD MILLION)
TABLE 293. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 294. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 296. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 298. GLOBAL MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • UCB S.A.
  • Viela Bio, Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 36.11 Billion
Forecasted Market Value ( USD ) by 2032 $ 58.34 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032 - Product Image

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Neurodegenerative Drugs Market - Global Forecast 2026-2032 - Product Image

Neurodegenerative Drugs Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Multiple Sclerosis Drugs - Global Strategic Business Report - Product Image

Multiple Sclerosis Drugs - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From
Multiple Sclerosis Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Multiple Sclerosis Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 90 Pages
  • Global
From
Multiple Sclerosis Therapeutic Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Region, 2025-2035 - Product Image

Multiple Sclerosis Therapeutic Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From

About the Market

The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected. MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants. The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.